A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...

As the push to integrate artificial intelligence and increase interoperability evolves, Clinical Architecture sees a dire need for tools that can assess the quality of healthcare data. Poor quality ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

Founder & CEO of CalmWave, Ophir Ronen is a 25-year Enterprise IT veteran, merging AI with healthcare to improve hospital operations. If hospital IT professionals are the unsung heroes of the ...

More than two years after the FDA held a public workshop on measuring overall survival (OS) in clinical cancer trials, the agency has released a draft guidance on the topic, recommending that OS be ...

In Mendelian inheritance patterns, you receive one version of a gene, called an allele, from each parent. These alleles can be dominant or recessive. Non-Mendelian genetics don’t completely follow ...

Personally identifiable information has been found in DataComp CommonPool, one of the largest open-source data sets used to train image generation models. Millions of images of passports, credit cards ...

Intermountain Health, the largest nonprofit healthcare provider in the Intermountain West region, struck a multi-year collaboration with a young generative AI startup this month. The health system is ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

Forbes contributors publish independent expert analyses and insights. Sai writes about healthcare, innovation and technology. Founder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris ...